A privately-held small biopharmaceutical corporation, BioPROVAR was founded by the principals following the discovery - and granting of patent portfolio - having the capability to prevent/downregulate hyperactivation of the primary responder immune cells generating and regulating both phases of the immune response. Normally present in the human body exerting immune regulation, this biological is no intrinsic toxicity. However, various conditions (eg an infection) can induce a deregulated hyperactive primary immune response causing an excess of inflammation that have een shown by studies to be at the core of many diseases. Peoples afflicted with inflammatory bowel diseases (IBD), sepsis, acute respiratory distress syndrome (ARDS), and demyelinating diseases known as multiple sclerosis (MS) where the myelin sheet around the nerves is destroyed by the immune cells, have a deregulated overactive primary immune response producing an excess release of inflammatory mediators. Currently available medications do not target the primary immune response. Instead the effort is attempt neutralization of the inflammatory mediators after their release. The BioPROVAR approach - use BioTremvarTM - is to target main activation pathway of primary responder immune cells to cut off the oversupply of inflammatory mediators causing the excess of inflammation and brings back a regulated primary immune response. BioTremvarTM therapeutic action serves to restore mmune balance - allowing the body to regain health. In a related but more recent endeavor, BioPROVAR is developing BioTremvar(TM), a biotherapeutical to alleviate ARDS and sepsis, the cause of death in COVID-19 patients
